SCHEMBL4912207

SCHEMBL4912207

CCCON1CCOCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 3/20 0.38
CYP1A2 P05177 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
HTR2A P28223 1/20 0.38
SCN1A P35498 1/20 0.38
HTR2B P41595 1/20 0.38
KCNH2 Q12809 1/20 0.38
SCN2A Q99250 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
SCN3A Q9NY46 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
USP2 O75604 1/20 0.37
TSHR P16473 2/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911938 0.86 LMNA (0.49) LMNASMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL5141114 0.85 SMN1; SMN2 (0.43) LMNASMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL8972595 0.83 LMNA (0.42) LMNASMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL30540107 0.83 LMNA (0.42) LMNASMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL16104935 0.82
SCHEMBL465014 0.80
SCHEMBL4823292 0.78 TSHR (0.36) SMN1; SMN2POLBALDH1A1USP2TSHR
SCHEMBL28331780 0.78 TSHR (0.42) LMNASMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL8703416 0.77
SCHEMBL2269684 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106854185-A A kind of preparation method of Gefitinib 湖南华腾制药有限公司 2017-06-16 CN claimed
CN-106854184-A The synthetic method of Gefitinib 湖南华腾制药有限公司 2017-06-16 CN claimed
WO-2007016156-A2 TOPICAL ANTI-PRURITIC COMPOSITIONS AND METHODS OF ACTION OF SAME STIEFEL LABORATORIES, INC. (US) 2007-02-08 WO claimed
CN-118298910-A Medicine target spot and medicine key pharmacophore detection method based on gene and medicine atomic interaction relation extraction method 浙江大学 2024-07-05 CN disclosed
US-11912647-B2 Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-02-27 US disclosed
CN-104628651-B Morpholine nitre azoles isomers and preparation method thereof 江苏豪森药业集团有限公司 2018-07-24 CN disclosed
CN-106854185-A A kind of preparation method of Gefitinib 湖南华腾制药有限公司 2017-06-16 CN disclosed
CN-106854185-A A kind of preparation method of Gefitinib 湖南华腾制药有限公司 2017-06-16 CN disclosed
CN-106854184-A The synthetic method of Gefitinib 湖南华腾制药有限公司 2017-06-16 CN disclosed
CN-106854184-A The synthetic method of Gefitinib 湖南华腾制药有限公司 2017-06-16 CN disclosed
CN-102718722-B The novel fragrant phenoxy ramification of carboxylic esters preparations and applicatio research that a kind of water oil is double molten NANKAI UNIVERSITY (CN) 2016-02-17 CN disclosed
CN-104640843-A 1-(cycloalkyl-carbonyl)proline derivative DAINIPPON SUMITOMO PHARMA CO 2015-05-20 CN disclosed
CN-102898386-A Quinazoline derivative, preparation method, intermediate, composition and application SHANGHAI PHARMACEUTICALS HOLDING CO LTD 2013-01-30 CN disclosed
CN-102718722-A Preparation and application research of water-soluble and oil-soluble novel aryloxy phenoxy carboxylate derivatives UNIV NANKAI 2012-10-10 CN disclosed
CN-102153518-B Preparation method of Gefitinib JIANGSU FARMTEC RES CO LTD 2012-10-10 CN disclosed
US-20120083602-A1 BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA MILLENNIUM PHARMACEUTICALS, INC. 2012-04-05 US disclosed
CN-102153518-A Preparation method of Gefitinib JIANGSU FARMTEC RES CO LTD 2011-08-17 CN disclosed
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PFIZER INC. 2008-08-21 US disclosed
EP-1866317-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-19 EP disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PF4, TBXA2R, P2RY4 LMNA 3156/4885SMN1; SMN2 3818/4885POLB 1500/4885
US-20120083602-A1 BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA TFPI, F12, TFPI2 LMNA 218/4885SMN1; SMN2 1977/4885POLB 2792/4885
US-11912647-B2 Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation ADH5, ADH1A, NAT1 LMNA 3243/4885SMN1; SMN2 2652/4885POLB 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.